Biophytis to Present Sarconeos at BIO International Convention
| Field | Detail |
|---|---|
| Company | Biophytis SA |
| Form Type | 6-K |
| Filed Date | Jun 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: conference-participation, drug-development, biotechnology
TL;DR
Biophytis is at BIO Intl Conv in San Diego this week to pitch its drug Sarconeos for cardiorespiratory diseases.
AI Summary
On June 4, 2025, Biophytis S.A. announced its participation in the BIO International Convention, held from June 3-6, 2025, in San Diego, California. The company plans to present its drug candidate, Sarconeos (BIO101), and discuss its potential in treating cardiorespiratory diseases. Biophytis aims to engage with potential partners and investors during the event.
Why It Matters
Biophytis' participation at a major industry event like the BIO International Convention is crucial for showcasing its lead drug candidate, Sarconeos, and attracting potential partnerships or investments for its development.
Risk Assessment
Risk Level: medium — The company is presenting a drug candidate, indicating it is still in development stages with inherent clinical and regulatory risks.
Key Players & Entities
- Biophytis S.A. (company) — Registrant and presenter
- Sarconeos (BIO101) (drug_candidate) — Drug candidate to be presented
- BIO International Convention (event) — Event Biophytis is attending
- June 4, 2025 (date) — Date of press release
- June 3-6, 2025 (date) — Dates of the convention
- San Diego, California (location) — Location of the convention
- Stanislas Veillet (person) — Contact person for Biophytis
FAQ
What is the primary purpose of Biophytis' participation in the BIO International Convention?
Biophytis is participating to present its drug candidate, Sarconeos (BIO101), and to engage with potential partners and investors regarding its development for cardiorespiratory diseases.
When and where is the BIO International Convention taking place?
The BIO International Convention is taking place from June 3-6, 2025, in San Diego, California.
What is the name of Biophytis' drug candidate being highlighted?
The drug candidate being highlighted is Sarconeos, also known as BIO101.
What type of diseases is Sarconeos intended to treat?
Sarconeos is intended to treat cardiorespiratory diseases.
What is the filing date of this Form 6-K report?
This Form 6-K report was filed on June 4, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 4, 2025 by Stanislas Veillet regarding Biophytis SA.